|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGBL5 |
Gene summary for AGBL5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGBL5 | Gene ID | 60509 |
| Gene name | AGBL carboxypeptidase 5 | |
| Gene Alias | CCP5 | |
| Cytomap | 2p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8NDL9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 60509 | AGBL5 | LZE4T | Human | Esophagus | ESCC | 4.46e-03 | 2.50e-01 | 0.0811 |
| 60509 | AGBL5 | LZE7T | Human | Esophagus | ESCC | 1.15e-05 | 3.88e-01 | 0.0667 |
| 60509 | AGBL5 | LZE8T | Human | Esophagus | ESCC | 1.78e-02 | 1.64e-01 | 0.067 |
| 60509 | AGBL5 | LZE22T | Human | Esophagus | ESCC | 4.70e-07 | 3.31e-01 | 0.068 |
| 60509 | AGBL5 | LZE24T | Human | Esophagus | ESCC | 1.84e-17 | 4.81e-01 | 0.0596 |
| 60509 | AGBL5 | P1T-E | Human | Esophagus | ESCC | 1.54e-04 | 1.45e-01 | 0.0875 |
| 60509 | AGBL5 | P2T-E | Human | Esophagus | ESCC | 1.21e-34 | 6.60e-01 | 0.1177 |
| 60509 | AGBL5 | P4T-E | Human | Esophagus | ESCC | 1.73e-05 | 1.45e-01 | 0.1323 |
| 60509 | AGBL5 | P5T-E | Human | Esophagus | ESCC | 1.20e-02 | 8.81e-02 | 0.1327 |
| 60509 | AGBL5 | P8T-E | Human | Esophagus | ESCC | 3.67e-07 | 1.08e-01 | 0.0889 |
| 60509 | AGBL5 | P9T-E | Human | Esophagus | ESCC | 1.42e-05 | 9.76e-02 | 0.1131 |
| 60509 | AGBL5 | P10T-E | Human | Esophagus | ESCC | 2.34e-22 | 3.69e-01 | 0.116 |
| 60509 | AGBL5 | P11T-E | Human | Esophagus | ESCC | 4.21e-08 | 3.44e-01 | 0.1426 |
| 60509 | AGBL5 | P12T-E | Human | Esophagus | ESCC | 1.09e-16 | 1.87e-01 | 0.1122 |
| 60509 | AGBL5 | P15T-E | Human | Esophagus | ESCC | 9.02e-15 | 3.57e-01 | 0.1149 |
| 60509 | AGBL5 | P16T-E | Human | Esophagus | ESCC | 1.08e-25 | 4.53e-01 | 0.1153 |
| 60509 | AGBL5 | P17T-E | Human | Esophagus | ESCC | 4.98e-03 | 1.96e-01 | 0.1278 |
| 60509 | AGBL5 | P20T-E | Human | Esophagus | ESCC | 3.11e-09 | 3.16e-01 | 0.1124 |
| 60509 | AGBL5 | P21T-E | Human | Esophagus | ESCC | 2.46e-18 | 3.40e-01 | 0.1617 |
| 60509 | AGBL5 | P22T-E | Human | Esophagus | ESCC | 5.12e-25 | 5.47e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:000961516 | Oral cavity | LP | response to virus | 143/4623 | 367/18723 | 7.42e-10 | 3.52e-08 | 143 |
| GO:005160711 | Oral cavity | LP | defense response to virus | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| GO:014054611 | Oral cavity | LP | defense response to symbiont | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGBL5 | SNV | Missense_Mutation | c.1195N>T | p.Leu399Phe | p.L399F | Q8NDL9 | protein_coding | tolerated(0.05) | benign(0.022) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGBL5 | SNV | Missense_Mutation | rs747191439 | c.1417G>A | p.Asp473Asn | p.D473N | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | c.793N>G | p.Phe265Val | p.F265V | Q8NDL9 | protein_coding | tolerated(0.12) | probably_damaging(0.999) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| AGBL5 | SNV | Missense_Mutation | novel | c.1072N>T | p.Pro358Ser | p.P358S | Q8NDL9 | protein_coding | tolerated(0.22) | benign(0.174) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | novel | c.1474N>T | p.Gly492Cys | p.G492C | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | c.610N>A | p.Arg204Ser | p.R204S | Q8NDL9 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGBL5 | SNV | Missense_Mutation | rs776394116 | c.2117A>G | p.Gln706Arg | p.Q706R | Q8NDL9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | novel | c.1649N>G | p.Tyr550Cys | p.Y550C | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | rs766193452 | c.971C>T | p.Pro324Leu | p.P324L | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGBL5 | SNV | Missense_Mutation | novel | c.80C>A | p.Ser27Tyr | p.S27Y | Q8NDL9 | protein_coding | deleterious(0.03) | benign(0.129) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |